New and emerging treatments for vitiligo: a narrative review.

INTRODUCTION

Vitiligo is a chronic autoimmune skin disorder characterized by progressive melanocyte loss, resulting in well-demarcated depigmented patches that significantly impact quality of life. Affecting 0.5-2% of the global population, vitiligo poses both psychosocial and therapeutic challenges. Despite multiple conventional therapies such as corticosteroids, calcineurin inhibitors, and phototherapy, durable repigmentation remains difficult to achieve.

AREAS COVERED: This review summarizes recent advances in understanding the emerging medical treatment of vitiligo. A targeted literature search was conducted using PubMed, Embase, and ClinicalTrials.gov from inception to April 2025. Key clinical trial data are discussed to evaluate efficacy, safety and durability of response across therapeutic classes.

EXPERT OPINION: The approval of topical ruxolitinib marks a pivotal step toward precision therapy in vitiligo. Ongoing studies of combination and maintenance regimens offer promise for sustained repigmentation and disease stabilization. However, optimizing long-term outcomes requires continued translational research to elucidate mechanisms of relapse, improve accessibility of emerging therapies and personalize treatment strategies to individual disease phenotypes.